EJNMMI Research

Table 1 Summary of blood pharmacokinetics

From: Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

Construct/protein dose (mg/kg)	Percent	Half-life (h)
¹¹¹In-DTPA-anti-PD-L1-BC/1	93	7
¹¹¹In-DTPA-anti-PD-L1-BC/1	7	32
¹¹¹In-DTPA-anti-PD-L1-BC/3	95	14
¹¹¹In-DTPA-anti-PD-L1-BC/3	5	46
¹¹¹In-DTPA-anti-PD-L1-BC/10^a	100	21
²²⁵Ac-DOTA-anti-PD-L1-BC/3	63	6
²²⁵Ac-DOTA-anti-PD-L1-BC/3	37	19

^a1-h measurement not available, blood curve was fit to a single-phase exponential function

Back to article page